Stephen Rubino

Chief Executive Officer

Professional Overview

Stephen Rubino is an accomplished biopharmaceutical executive with over 30 years of experience driving strategic growth and commercial success. As the Chief Executive Officer of Sporos Bioventures, he leverages his deep industry expertise to lead the company's mission of developing innovative therapies to address unmet medical needs. Rubino's versatile background spans roles in investor relations, strategic planning, business development, and global marketing, equipping him with a well-rounded skill set to navigate the complex biopharmaceutical landscape.

Experience Summary

Current Role

As the Chief Executive Officer of Sporos Bioventures since September 2022, Rubino is responsible for setting the strategic vision and overseeing all aspects of the company's operations. He is driving the advancement of Sporos Bioventures' pipeline of promising drug candidates and fostering collaborative partnerships to accelerate the development and commercialization of novel therapeutics.

In addition to his CEO role, Rubino serves as an Independent Member on the Board of Directors for Viracta Therapeutics, Inc., a position he has held since March 2021. In this capacity, he provides strategic guidance and oversight to support the company's efforts in developing targeted therapies for hematologic malignancies and solid tumors.

Career Progression

Prior to his current roles, Rubino held several senior-level positions within the biopharmaceutical industry. Most recently, he served as the Chief Business Officer at Celyad Oncology, where he was instrumental in shaping the company's strategic direction and overseeing key business operations from February 2020 to April 2022.

Rubino's extensive experience includes serving as an Independent Member on the Board of Directors for Sermonix Pharmaceuticals from 2019 to 2021 and Ilkos Therapeutic from 2017 to 2020. Earlier in his career, he held various leadership roles at Novartis, including Vice President of Investor Relations North America, Vice President of Strategic Planning and Business Development, and Vice President of New Product Commercialization Marketing. Prior to Novartis, Rubino served as the Global Marketing Head for the Solid Tumor and AutoImmune Business Unit at Schering-Plough.

Academic Background

Rubino holds a strong academic background, having earned his education from prestigious institutions.

Areas of Expertise

Rubino's diverse career has equipped him with a comprehensive set of skills and expertise, including:

Strategic planning and business development

Investor relations and capital markets

Global marketing and commercialization

Therapeutic pipeline and portfolio management

Collaborative partnerships and alliance management

Leadership and organizational management

Professional Impact

Throughout his distinguished career, Rubino has made significant contributions to the biopharmaceutical industry. He has played a pivotal role in driving the strategic growth and commercial success of several leading healthcare companies, leveraging his deep industry knowledge and robust leadership capabilities to navigate complex challenges and capitalize on emerging opportunities.

Conclusion

With his extensive experience, proven track record of success, and a steadfast commitment to advancing innovative therapies, Stephen Rubino is poised to continue making a meaningful impact as the Chief Executive Officer of Sporos Bioventures. His versatile skill set and industry expertise position him as a valuable asset in the biopharmaceutical sector, where he remains dedicated to improving patient outcomes and delivering long-term value for stakeholders.